Nassar Amin H, Abdul-Jawad Baraa M, Barnes David S
Department of Pulmonary Medicine and Critical Care, Brigham and Women's Hospital, Boston, MA.
Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH.
ACG Case Rep J. 2018 Jan 17;5:e6. doi: 10.14309/crj.2018.6. eCollection 2018.
Hepatitis C-induced cholestatic hepatitis is a well-known fatal complication of postorthotropic liver transplantation and prolonged immunosuppression. Recent studies on direct-acting antiviral agents have shown promising results in terms of morbidity and mortality of this condition in postorthotropic liver, heart, and renal transplant patients. However, hepatitis C-induced cholestatic hepatitis remains a highly fatal condition in non-transplant patients. We report the first-ever use of the oral direct-acting antiviral combination, elbasvir and grazeprevir, in the treatment of a non-liver transplant patient with cholestatic hepatitis.
丙型肝炎引起的胆汁淤积性肝炎是原位肝移植术后及长期免疫抑制的一种众所周知的致命并发症。近期关于直接作用抗病毒药物的研究表明，在原位肝移植、心脏移植和肾移植患者中，该药物对于这种病症的发病率和死亡率有令人鼓舞的效果。然而，丙型肝炎引起的胆汁淤积性肝炎在非移植患者中仍然是一种高致死性病症。我们报告了首例使用口服直接作用抗病毒药物组合艾尔巴韦和格拉瑞韦治疗非肝移植胆汁淤积性肝炎患者的案例。
